Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNEU-WAY PED
2019-000341-12Phase 3
- Sponsor
- Merck & Co.
- Start
- Nov 2019
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pneumococcal disease comparing V114 followed by PNEUMOVAX 23 with Active comparator followed by PNEUMOVAX 23 (2 arms). Primary endpoint: Percentage of participants with a solicited injection-site adverse event after Vaccination 1.
02
Drugs
pneumococcal 15-valent conjugate vaccine23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2019-000341-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000341-12.